BriaCell Bria-IMT Phase 2 OS 16.6 months; Positive Phase 3 QOL data
BriaCell Therapeutics announced positive clinical data from its Bria-IMT studies, presented at the 2026 ASCO Annual Meeting. The final Phase 2 data showed a median overall survival of 16.6 months with the Phase 3 formulation, with 52% of patients surviving at 12 months and 26% at 24 months. Additionally, the ongoing pivotal Phase 3 study demonstrated positive Quality of Life data, indicating preserved QOL and meaningful benefits without significant toxicity for heavily pre-treated metastatic breast cancer patients. Biomarker analyses from the Phase 3 study also confirmed predictors of anti-cancer response, with 65% of patients showing stable or dropping Cancer-Associated Macrophage-Like cells correlating with better progression-free survival.
Key Highlights
- Final Phase 2 Bria-IMT median overall survival (OS) was 16.6 months with the Phase 3 formulation.
- Phase 2 data showed 52% of patients survived at 12 months with the Phase 3 formulation.
- Phase 2 data indicated a 24-month survival rate of 26% in heavily pretreated MBC patients.
- Phase 3 study showed stable global health and key functional domains, preserving quality of life.
- Phase 3 biomarker analysis found 65% of patients with stable/dropping CAMLs correlated with better progression-free survival.
- The Bria-IMT regimen demonstrated a tolerable safety profile with no treatment-related discontinuations.
Price Impact
More from BCTX